Kaili Xie obtains MSCA fellowship for spray delivery research
Respiratory diseases are one of the leading causes of death worldwide. The recent global pandemic of SARS-CoV-2 has made us realize that effective and widely acceptable therapies against such diseases are still lacking and are urgently needed. Administering drugs directly to the lungs through aerosols, tiny droplets in the air, enables targeted therapeutic effects while minimizing side effects by reducing systemic drug exposure. However, the drug deposition in lungs is very poor.
The aim of this project is to develop a low shear nebulization to enhance drug delivery to the lungs via aerosols. He will use this optimized nebulization method to investigate how medication aerosols impact on the mucus in the respiratory tract, and devise strategies to enhance targeted aerosol deposition. In addition, he will investigate the transport of drug particles within the airways mucus. The project will establish transformable and applicable technologies for advancing aerosol drug delivery to the respiratory tract.
